We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
When Kåre Schultz joined Teva as CEO back in November 2017, the drugmaker was in a world of hurt. It was saddled with debt, costs were high and sales were falling.
Spare a thought for Kare Schultz, he agreed to take on the position of CEO at Teva at the start of September and, reportedly, arrived for his first day of work at the company yesterday.